Stimulating the brain's immune response may provide treatment for Alzheimer's disease

Jan 26, 2011

A new target for the prevention of adverse immune responses identified as factors in the development of Alzheimer's disease (AD) has been discovered by researchers at the University of South Florida's Department of Psychiatry and the Center of Excellence for Aging and Brain Repair.

Their findings are published online in the Journal of Neuroscience.

The CD45 molecule is a receptor on the surface of the brain's microglia cells, cells that support the brain's and also participate in brain immune responses.

Previous studies by the USF researchers showed that triggering CD45 was beneficial because it blocked a very early step in the development of Alzheimer's disease. In the present study, the researchers demonstrated in Alzheimer's mouse models that a loss of CD45 led to dramatically increased microglial inflammation.

Although the brain's is involved in Alzheimer's disease pathology, "this finding suggests that CD45 on brain appears critically involved in dampening harmful inflammation," said study senior author Jun Tan, MD, PhD, a professor of psychiatry and Robert A. Silver chair at the Rashid Laboratory for Developmental Neurobiology, USF Silver Child Development Center and research biologist for Research and Development Service at the James A. Haley Veteran's Hospital.

The investigators also found an increase in harmful , such as A beta , as well as neuron loss in the brains of the test mice.

"In short, CD45 deficiency leads to increased accumulation of neurotoxic A beta in the brains of old Alzheimer's mice, demonstrating the involvement of CD45 in clearing those toxins and protecting neurons," Dr. Tan said. "These findings are quite significant, because many in the field have long considered CD45 to be an indicator of harmful . So, researchers assumed that CD45 was part of the problem, not a potential protective factor."

The next step is to apply these findings to develop new Alzheimer's disease treatments, said Paula Bickford, PhD, a professor in the USF Department of Neurosurgery and senior career research scientist at the James A. Haley Veteran's Hospital.

"We are already working with Natura Therapeutics, Inc. to screen for natural compounds that will target CD45 activation in the brain's immune cells," Dr. Bickford said.

Explore further: REM sleep critical for young brain development; medication interferes

More information: http://www.jneurosci.org/

Related Stories

Team studies T cell activation with nanoparticles

Apr 28, 2010

A University of Alberta-led research team has taken a major step forward in understanding how T cells are activated in the course of an immune response by combining nanotechnology and cell biology. T cells are the all important ...

Recommended for you

Making waves with groundbreaking brain research

Jul 03, 2015

New research by Jason Gallivan and Randy Flanagan suggests that when deciding which of several possible actions to perform, the human brain plans multiple actions simultaneously prior to selecting one of ...

Long-term memories are maintained by prion-like proteins

Jul 02, 2015

Research from Eric Kandel's lab at Columbia University Medical Center (CUMC) has uncovered further evidence of a system in the brain that persistently maintains memories for long periods of time. And paradoxically, ...

Water to understand the brain

Jul 02, 2015

To observe the brain in action, scientists and physicians use imaging techniques, among which functional magnetic resonance imaging (fMRI) is the best known. These techniques are not based on direct observations ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.